Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15209482 | 1.00 | ALOX15 (0.44) | ALOX15TSHRSLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL29071916 | 0.92 | ALOX15 (0.39) | ALOX15TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24312400 | 0.90 | CYP2D6 (0.38) | SLC6A2SLC6A4SLC6A3L3MBTL1CYP2D6 | |
| SCHEMBL7155286 | 0.89 | CYP2D6 (0.37) | SLC6A2SLC6A4SLC6A3L3MBTL1CYP2D6 | |
| SCHEMBL3834273 | 0.88 | SLC6A2 (0.36) | ALOX15TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2531862 | 0.87 | CYP1A2 (0.42) | TSHRCYP2D6SMN1; SMN2CYP3A4HTT | |
| SCHEMBL21873649 | 0.87 | CYP1A2 (0.42) | TSHRCYP2D6SMN1; SMN2CYP3A4HTT | |
| SCHEMBL218117 | 0.87 | CYP1A2 (0.42) | TSHRCYP2D6SMN1; SMN2CYP3A4HTT | |
| SCHEMBL6158503 | 0.86 | CYP3A4 (0.37) | TSHRL3MBTL1CYP2D6SMN1; SMN2CYP3A4 | |
| SCHEMBL26103074 | 0.85 | SLC6A2 (0.39) | ALOX15TSHRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209102-B2 | Heterocyclic compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4489738-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| CN-118019742-A | Novel benzodiazepine derivatives as GABA Aγ1 PAM | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-9458177-B2 | Oxazolidin-2-one compounds and uses thereof | NOVARTIS AG (CH) | 2016-10-04 | — | — | US | disclosed |
| EP-2817307-B1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2817307-A1 | OXAZOLIDIN- 2 -ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS | Novartis AG (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-20140378450-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| US-8865894-B2 | Oxazolidin-2-one compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130225574-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| WO-2013124826-A1 | OXAZOLIDIN- 2 -ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS | NOVARTIS AG (CH) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | ALOX15 4537/4885TSHR 2508/4885SLC6A2 4716/4885 |
| US-20140378450-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALOX15 3317/4885TSHR 3875/4885SLC6A2 4749/4885 |
| US-12209102-B2 | Heterocyclic compounds and uses thereof | TP53, HRAS, KRAS | ALOX15 4537/4885TSHR 2508/4885SLC6A2 4716/4885 |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | ALOX15 4537/4885TSHR 2508/4885SLC6A2 4716/4885 |
| US-20130225574-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALOX15 3317/4885TSHR 3875/4885SLC6A2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.